Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 38.54 Billion JPY | 1347.28% |
| 2023 | -3.09 Billion JPY | -108.61% |
| 2022 | 35.88 Billion JPY | 177.82% |
| 2021 | 12.91 Billion JPY | -61.48% |
| 2020 | 33.53 Billion JPY | -25.64% |
| 2019 | 45.09 Billion JPY | 16.56% |
| 2018 | 38.69 Billion JPY | 19.13% |
| 2017 | 32.47 Billion JPY | -59.49% |
| 2016 | 80.18 Billion JPY | 126.66% |
| 2015 | 35.37 Billion JPY | 29.04% |
| 2014 | 27.41 Billion JPY | 11.07% |
| 2013 | 24.68 Billion JPY | -7.68% |
| 2012 | 26.73 Billion JPY | -13.03% |
| 2011 | 30.73 Billion JPY | 3.7% |
| 2010 | 29.64 Billion JPY | 91.3% |
| 2009 | 15.49 Billion JPY | -23.94% |
| 2008 | 20.37 Billion JPY | -0.21% |
| 2007 | 20.41 Billion JPY | -2.78% |
| 2006 | 20.99 Billion JPY | 10.6% |
| 2005 | 18.98 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | 51.9 Billion JPY | 1779.71% |
| 2024 Q1 | 12.75 Billion JPY | 80.67% |
| 2024 Q4 | 11.1 Billion JPY | 0.38% |
| 2024 Q3 | 11.05 Billion JPY | -10.46% |
| 2024 Q2 | 12.35 Billion JPY | -3.14% |
| 2023 Q1 | 8.33 Billion JPY | -12.34% |
| 2023 Q3 | 8.87 Billion JPY | 132.44% |
| 2023 FY | -3.09 Billion JPY | -108.61% |
| 2023 Q4 | 7.05 Billion JPY | -20.48% |
| 2023 Q2 | -27.35 Billion JPY | -428.26% |
| 2022 Q3 | 7.57 Billion JPY | -21.5% |
| 2022 Q2 | 9.65 Billion JPY | 1.18% |
| 2022 Q1 | 9.53 Billion JPY | 166.46% |
| 2022 Q4 | 9.5 Billion JPY | 25.49% |
| 2022 FY | 35.88 Billion JPY | 177.82% |
| 2021 Q1 | 8.01 Billion JPY | 74.53% |
| 2021 FY | 12.91 Billion JPY | -61.48% |
| 2021 Q3 | 8.58 Billion JPY | -19.58% |
| 2021 Q4 | -14.35 Billion JPY | -267.24% |
| 2021 Q2 | 10.67 Billion JPY | 33.11% |
| 2020 FY | 33.53 Billion JPY | -25.64% |
| 2020 Q4 | 4.59 Billion JPY | -53.75% |
| 2020 Q3 | 9.93 Billion JPY | 1.69% |
| 2020 Q1 | 9.24 Billion JPY | -19.19% |
| 2020 Q2 | 9.76 Billion JPY | 5.62% |
| 2019 Q4 | 11.44 Billion JPY | -10.84% |
| 2019 FY | 45.09 Billion JPY | 16.56% |
| 2019 Q1 | 10.01 Billion JPY | 16.41% |
| 2019 Q2 | 10.8 Billion JPY | 7.92% |
| 2019 Q3 | 12.83 Billion JPY | 18.72% |
| 2018 Q2 | 8.98 Billion JPY | -25.49% |
| 2018 FY | 38.69 Billion JPY | 19.13% |
| 2018 Q4 | 8.6 Billion JPY | -4.91% |
| 2018 Q3 | 9.04 Billion JPY | 0.72% |
| 2018 Q1 | 12.05 Billion JPY | 141.55% |
| 2017 FY | 32.47 Billion JPY | -59.49% |
| 2017 Q4 | 4.99 Billion JPY | -42.63% |
| 2017 Q3 | 8.7 Billion JPY | 9.08% |
| 2017 Q2 | 7.97 Billion JPY | -26.22% |
| 2017 Q1 | 10.81 Billion JPY | 87.72% |
| 2016 Q4 | 5.75 Billion JPY | -36.27% |
| 2016 Q2 | 54.58 Billion JPY | 405.47% |
| 2016 FY | 80.18 Billion JPY | 126.66% |
| 2016 Q1 | 10.79 Billion JPY | -2.16% |
| 2016 Q3 | 9.03 Billion JPY | -83.45% |
| 2015 FY | 35.37 Billion JPY | 29.04% |
| 2015 Q3 | 11.14 Billion JPY | 42.8% |
| 2015 Q1 | 5.39 Billion JPY | 42.58% |
| 2015 Q2 | 7.8 Billion JPY | 44.74% |
| 2015 Q4 | 11.03 Billion JPY | -0.95% |
| 2014 Q2 | 6.64 Billion JPY | -14.99% |
| 2014 Q3 | 9.17 Billion JPY | 38.13% |
| 2014 Q4 | 3.78 Billion JPY | -58.79% |
| 2014 FY | 27.41 Billion JPY | 11.07% |
| 2014 Q1 | 7.81 Billion JPY | 90.17% |
| 2013 Q1 | 6.12 Billion JPY | 35.65% |
| 2013 Q2 | 6.95 Billion JPY | 13.66% |
| 2013 Q3 | 7.49 Billion JPY | 7.67% |
| 2013 FY | 24.68 Billion JPY | -7.68% |
| 2013 Q4 | 4.1 Billion JPY | -45.15% |
| 2012 FY | 26.73 Billion JPY | -13.03% |
| 2012 Q4 | 4.51 Billion JPY | -41.01% |
| 2012 Q1 | 7.76 Billion JPY | -10.07% |
| 2012 Q3 | 7.65 Billion JPY | 12.37% |
| 2012 Q2 | 6.8 Billion JPY | -12.29% |
| 2011 Q1 | 6.63 Billion JPY | 68.84% |
| 2011 Q4 | 8.63 Billion JPY | 7.97% |
| 2011 FY | 30.73 Billion JPY | 3.7% |
| 2011 Q2 | 7.47 Billion JPY | 12.61% |
| 2011 Q3 | 7.99 Billion JPY | 6.96% |
| 2010 Q1 | 10.3 Billion JPY | 157.89% |
| 2010 FY | 29.64 Billion JPY | 91.3% |
| 2010 Q4 | 3.93 Billion JPY | -41.08% |
| 2010 Q2 | 8.72 Billion JPY | -15.33% |
| 2010 Q3 | 6.67 Billion JPY | -23.56% |
| 2009 FY | 15.49 Billion JPY | -23.94% |
| 2009 Q2 | 5.74 Billion JPY | 0.0% |
| 2009 Q3 | 5.86 Billion JPY | 2.11% |
| 2009 Q4 | 3.99 Billion JPY | -31.8% |
| 2008 FY | 20.37 Billion JPY | -0.21% |
| 2007 FY | 20.41 Billion JPY | -2.78% |
| 2006 FY | 20.99 Billion JPY | 10.6% |
| 2005 FY | 18.98 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -370.414% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | -123.53% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -449.329% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 97102.416% |
| Novartis AG | 9.76 Billion USD | -294.523% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 98.937% |